Synapse - Howard Scher

Search Within

Howard Scher

Results (1133)

Association of baseline corticosteroid with outcomes in a multivariate analysis of the phase 3 AFFIRM study of enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI)

Meeting Abstract

Scher, H. I.; Fizazi, K.; Saad, F.; Chi, K.; Taplin, M.; Sternberg, C. N.; Armstrong, A. J.; Hirmand, M.; Selby, B.; de Bono, J. S.
Annals of Oncology (2012)

Fulltext@MSK | Save

Association of radiographic progression-free survival (rPFS) adapted from Prostate Cancer Working Group 2 (PCWG2) consensus criteria (APCWG2) with overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302

Meeting Abstract

Ryan, C. J.; Morris, M.; Molina, A.; Piulats, J. R.; De Souza, P.; Li, J.; Kheoh, T.; de Bono, J. S.; Larson, S.; Griffin, T.; more...
Annals of Oncology (2012)

Fulltext@MSK | Save

ARN-509 in men with metastatic castration-resistant prostate cancer (CRPC)

Meeting Abstract

Rathkopf, D.; Antonarakis, E. S.; Shore, N. D.; Tutrone, R.; Alumkal, J.; Ryan, C. J.; Saleh, M.; Hauke, R.; Chow-Maneval, E.; Scher, H. I.
Annals of Oncology (2012)

Fulltext@MSK | Save

Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study

Meeting Abstract

Fizazi, K.; Scher, H. I.; Saad, F.; Sternberg, C. N.; Miller, K.; Mulders, P.; Chi, K.; Basch, E.; Hirmand, M.; de Bono, J. S.
Annals of Oncology (2012)

Fulltext@MSK | Save

The analytical validation of prostate specific mRNA detection in whole blood by reverse transcription-polymerase chain reaction (RT-PCR) as a prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)

Meeting Abstract

Danila, D.; Anand, A.; Heller, G.; Wan, M.; Zehnder, M.; Khanin, R.; Schultz, N.; Fleisher, M.; Lilja, H.; Scher, H. I.
Annals of Oncology (2012)

Fulltext@MSK | Save

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: A prospective study

Journal Article

Ross, R. W.; Galsky, M. D.; Scher, H. I.; Magidson, J.; Magidson, K.; Lee, G. S. M.; Katz, L.; Subudhi, S. K.; Anand, A.; Fleisher, M.; more...
Lancet Oncology (2012)

Fulltext@MSK | Save

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: A prospective, two-stage study

Journal Article

Olmos, D.; Brewer, D.; Clark, J.; Danila, D. C.; Parker, C.; Attard, G.; Fleisher, M.; Reid, A. H. M.; Castro, E.; Sandhu, S. K.; more...
Lancet Oncology (2012)

Fulltext@MSK | Save

Increased survival with enzalutamide in prostate cancer after chemotherapy

Journal Article

Scher, H. I.; Fizazi, K.; Saad, F.; Taplin, M. E.; Sternberg, C. N.; Miller, K.; De Wit, R.; Mulders, P.; Chi, K. N.; Shore, N. D.; more...
New England Journal of Medicine (2012)

Fulltext@MSK | Save

A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

Journal Article

Morris, M. J.; Eisenberger, M. A.; Pili, R.; Denmeade, S. R.; Rathkopf, D.; Slovin, S. F.; Farrelly, J.; Chudow, J. J.; Vincent, M.; Scher, H. I.; more...
Annals of Oncology (2012)

Fulltext@MSK | Save

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Journal Article

Fizazi, K.; Scher, H. I.; Molina, A.; Logothetis, C. J.; Chi, K. N.; Jones, R. J.; Staffurth, J. N.; North, S.; Vogelzang, N. J.; Saad, F.; more...
Lancet Oncology (2012)

Fulltext@MSK | Save